MPG.eBooks - Search Results - "Dermatology"

Cover Image

1

Pharmacoeconomic review report: Risankizumab (Skyrizi) (AbbVie)

Published 2019

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Dermatologic Agents / therapeutic use...”

Cover Image

2

Pharmacoeconomic review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.) : indication: for the treatment of adult patients with active ankylosing spondylitis who have responded i...

Published 2020

CADTH

Subjects: “...Dermatologic Agents / therapeutic use...”

Cover Image

3

CADTH Canadian Drug Expert Committee recommendation: Risankizumab (Skyrizi -- Abbvie) : indication : adult patients with moderate to severe plaque psoriasis

Published 2019

CADTH

Subjects: “...Dermatologic Agents / therapeutic use...”

Cover Image

4

CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication : adult patients with active psoriatic arthritis (PsA) who have respon...

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Dermatologic Agents / economics...”

Cover Image

5

CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication : adult patients with active psoriatic arthritis (PsA) who have respon...

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Dermatologic Agents / economics...”